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Case Report
Methamphetamine Associated Cardiomyopathy in
Pregnancy: The Distinctions and the Implications
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Methamphetamine associated cardiomyopathy (MAC) and peripartum cardiomyopathy
(PPCM) are both rare obstetric conditions. Literature regarding methamphetamine associated cardiomyopathy in the obstetric population is limited, and it can be difficult to make
the distinction between the two given the similarities in clinical presentation. However
similar, there are significant distinctions in the pathophysiology of these two that can help
clinicians with the management process.
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Clinical Findings and Outcomes

This case involves a 35-year-old Hispanic G6P5005 at 37 weeks gestation presenting with
acute respiratory failure secondary to acute decompensated heart failure with reduced
ejection fraction and superimposed preeclampsia leading to urgent cesarean section. The
patient’s course was also complicated by chronic methamphetamine use with a possible
withdrawal component, which resulted in rapid sequence intubation and mechanical ventilation. Ultimately the patient’s respiratory and cardiac symptoms resolved with appropriate
treatment. Resolution of reduced ejection fraction was also demonstrated by repeat echocardiogram.

Conclusions

In this article, we will compare the pathophysiology, diagnostic criteria, treatment and prognosis of MAC, specifically in pregnancy, versus PPCM. We also discuss how we ultimately
conclude that a diagnosis of MAC can be made rather than PPCM or stress cardiomyopathy.
We also find that studies involving methamphetamine use in pregnancy are limited, and
ultimately more longitudinal data is needed to achieve a better understanding of patient
outcomes, especially given the increasing prevalence of methamphetamine use in the United
States.
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Introduction

pertinent in any setting.

The field of critical care is all-encompassing and
applies to all specialties of medicine including
obstetrics. The number of obstetric conditions
requiring intensive care admission is relatively
small (compared to the general non child-bearing adult population) and is typically related to
hypertensive or hemorrhagic causes.1 However,
the rates of mortality with these conditions
can be as high as 60%.2 Thus, maintaining
knowledge of critical care obstetrics remains

Methamphetamine use is on the rise, and the
widespread pattern of abuse and household
production is reminiscent of the crack cocaine
epidemic of the 1980s. Data recently published
by the Centers for Disease Control and Prevention showed that between 2015 and 2018,
1.6 million Americans used methamphetamine
within the past year.3 A study from 2006
estimated that approximately 5% of women
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used methamphetamine during pregnancy, and
with current trends it is likely this number has
increased over time.4 With evidence of this extensive use, it is clear that physicians of all specialties will encounter patients suffering from
this addiction in a variety of different scenarios.
The case involves a patient presenting with
acute respiratory failure secondary to acute
decompensated heart failure with reduced
ejection fraction (EF) with superimposed preeclampsia leading to urgent cesarean section.
The patient’s course was also complicated by
chronic methamphetamine use (as confirmed
by a positive urine drug screen and the patient’s own admission) with a possible withdrawal component, which resulted in mechanical ventilation.
We will compare the pathophysiology, diagnostic criteria, clinical presentation and treatment
of methamphetamine associated cardiomyopathy (MAC) specifically in pregnancy, versus
peripartum cardiomyopathy (PPCM), both of
which are rare conditions.2,5,6 We also discuss
how we ultimately concluded that a diagnosis
of MAC could be made rather than PPCM or
stress-induced cardiomyopathy.

Case Presentation

A 35-year-old Hispanic G6P5005 at 37 weeks
gestation presented to the emergency department with a complaint of worsening shortness
of breath and lower extremity edema for the
past two days. Medical history included iron
deficiency anemia and methamphetamine use.
She reported having a history of new onset
hypertension during her first pregnancy prior

to 20 weeks gestation, which resolved with
no progression to gestational hypertension or
preeclampsia. She was normotensive during
the prenatal course for her current pregnancy
and was not prescribed any anti-hypertensive
medication. At presentation, she was in severe
preeclampsia (blood pressure above 160 mm
Hg with proteinuria) and desaturation (pulse
oximetry was 91% on room air) with crackles
in lung bases and pitting edema of the lower
extremities. Urine drug screen (UDS) was
positive for methamphetamine. Additional
urine and serum laboratory testing are listed in Table 1 and Table 2. A chest x-ray (CXR)
demonstrated bilateral edema with cardiomegaly. Bedside point of care echocardiography showed an estimated EF of 30–40%. The
patient was placed on non-invasive ventilation
(NIPPV) and admitted to the labor and delivery
service for an urgent cesarean section that was
done with epidural anesthesia. She received
intravenous (IV) furosemide and fentanyl, and
two units of packed red blood cells (PRBC) intraoperatively. The fetus was delivered without
complication.
Upon returning to the post-anesthesia care
unit (PACU), the patient’s blood pressure readings from the brachial artery cuff were in the
hypotensive range, and there was significant lochia. At this point, we had concerns for possible
hemorrhagic shock secondary to uterine atony.
A left radial arterial line was placed yielding
systolic BP readings in the 180s disproving this
theory, and we suspected the hypotensive value was due to an inaccurate telemetry from the
cuff or user error; however, due to the volume
of blood loss, she was transfused an additional

Table 1. Serum Labs.
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N-terminal Brain Natriuretic Peptide

580 pg/mL (5–125)

Serial Troponin I Level (3 sets measured 6
hours apart)

0, 0, 0.028 ng/mL (0–0.045)

Creatine Kinase

361 U/L (26–192)

Serum Creatinine

0.61 mg/dL (0.52–1.23)

Complete Blood Count

Hemoglobin: 6 gm/dL (12–16)
Hematocrit: 23.4% (37–47%)
Platelets: 309,000 (150,000–450,000)
White Blood Cells: 13,000 (4800–10800)

Liver Function Tests

Aspartate aminotransferase: 23 (15–37)
Alanine aminotransferase: 9 (12–78)
Alkaline phosphatase: 112 (45–117)
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Table 2. Urine Labs.
Urine Drug Screen

Amphetamine: positive
Cocaine: negative
THC: negative
Barbiturate: negative
Benzodiazepines: negative
Opiates: negative
PCP: negative

Urinalysis

Color: amber
Appearance: clear
Glucose: negative
Bilirubin: negative
Ketones: negative
Protein: 100 mg/dL (positive)
Nitrite: negative
Leukocyte esterase: negative
RBC: 0–2 (negative)
WBC: 0–2 (negative)
Epithelial cells: 2–5 (2–5)

Random Urine Protein

85.5 mg/dL (< 11.9)

Random Urine Creatinine

61.8 mg/dL

unit of PRBC. An IV nitroglycerin drip was then
started. A stat echocardiogram showed an EF
of 30–35% with moderate diffuse hypokinesis,
mildly increased wall thickness, grade 1 diastolic dysfunction and a normal left ventricle size.
Left ventricular end diastolic volume (LVEDV)
on 2 chamber and 4 chamber views were 61 ml
and 86 ml, respectively.

ordered (day 4 of admission), which showed
mild to moderate mitral regurgitation and improvement in ejection fraction to 55% to 60%
with mild left ventricular dilation and grade
1 diastolic dysfunction. She was discharged
home with follow up plans, and child protective
services were contacted regarding custody of
the newborn.

Upon transfer to the intensive care unit, she
continued to remain hypertensive despite
nitroglycerin and was now tachypneic and
tachycardic as well. The onset of tachycardia
was concerning for possible methamphetamine
withdrawal, and she was given lorazepam
with no resolve. Due to concern for imminent
respiratory compromise, she was intubated
and placed on mechanical ventilation. A dexmedetomidine drip was started for sedation.
Post-intubation CXR revealed persistent
interstitial edema with a new left-sided effusion, and arterial blood gas (ABG) revealed a
non-anion gap metabolic acidosis. Diuresis with
IV high dose furosemide was initiated.

Discussion

The following day, CXR was notable for improving edema and left-sided effusion. The patient
was extubated, and her blood pressure stabilized with carvedilol and hydralazine. The next
day, she was noted to have a new systolic murmur; therefore, a repeat echocardiogram was

We do not believe the symptoms were due
to peripartum cardiomyopathy. Peripartum
cardiomyopathy requires the following criteria
for diagnosis: presentation late in pregnancy
or several months postpartum, an EF less than
45% and the absence of prior cardiac disease or

The case presents a difficult diagnosis, as the
symptoms were multifactorial in nature. We
believe the symptoms stem from a combination of preeclampsia and methamphetamine
use rather than a case of PPCM, given methamphetamine use was an identifiable cause
of heart failure (this will be elaborated on
further). The diagnosis of preeclampsia with
severe features was made given two systolic blood pressure measurements above 160
mmHg with proteinuria (100 mg/dl on urinalysis and 85.5 mg/dL on random urine protein
sample) and the presence of pulmonary edema.7
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other identifiable causes of heart failure.2,5 Our
patient presented late in pregnancy (37 weeks
gestation). Echocardiogram on the day of
presentation was read by two different cardiologists with one reporting EF as 30–35% and
the other reporting it as 35–40%. The patient
only met 2 of the 3 criteria and could not be
diagnosed with peripartum cardiomyopathy as
chronic methamphetamine use can also cause
heart failure.
The exact underlying cause of PPCM is not
well understood, however there are several
proposed hypotheses in the current literature.
These include the combination of oxidative
stress and gestational hormone secretion
leading to vascular endothelial damage and
inflammation of cardiac myocytes. The main
hormone involved in this process is prolactin.8,9
Prolactin undergoes enzymatic cleavage to a
form known as 16-kDa prolactin which induces
apoptosis in cardiac myocytes. Another hormone, soluble Fms-like tyrosine kinase 1 (sFlt1),
is also thought to play a role in this process by
inhibiting the activity of vascular endothelial
growth factor (VEGF). There is also a possible
genetic component to PPCM. Patients with a
mutation in the TTN gene, which encodes the
sarcomere protein titin, were found to have a
genetic predisposition to dilated cardiomyopathy in a recent study.8,9,10
The primary mechanism through which methamphetamine causes cardiomyopathy is catecholamine excess and a hyperadrenergic
state.11 Methamphetamine is a Central Nervous
System (CNS) stimulant that acts by indirectly increasing levels of dopamine, serotonin,
norepinephrine and epinephrine. Schurer et al.
note that methamphetamine can have multiple
effects on the myocardium including “direct
toxic effects, vasospasm, ischemia, reactive oxygen species and mitochondrial and metabolic
alterations”.12 In their study, histopathological
analysis of the myocardium in a non-pregnant
patient with a minimum of 2 years of methamphetamine use was notable for fibrosis, myocyte damage and inflammation (characterized
by positive staining for CD3 T cells and CD68
macrophages).12
Data regarding methamphetamine associated cardiomyopathy in pregnancy is limited, as
most studies only involve non-pregnant women

60

or a majority male population. A recently published case series detailed MAC in five pregnant
patients, with four out of the five presenting
in the second trimester and one presenting in
the third trimester.6 In our case, the patient
admitted to using methamphetamine 2 weeks
prior to presentation and denied recent use;
however, her UDS on admission was positive.
Methamphetamine is detected up to 48 hours
after use in most standard drug tests and has a
half-life of 9 to 12 hours.13 Therefore, it is highly
likely the patient had recently used methamphetamine within that time frame.
The treatment for PPCM and MAC in pregnancy in the acute setting are consistent with
management of an acute heart failure exacerbation, i.e., optimization of respiratory status,
diuresis, beta blockade and if needed, hemodynamic support. Management of hypertension
is also an important component in the overall
scheme.
In cases of preeclampsia, labetalol is an effective anti-hypertensive. Although the current
literature on the use of labetalol in meth users
is limited and somewhat controversial. There
is a concern that giving labetalol in patients
with active methamphetamine use can worsen hypertension due to vasoconstriction from
unopposed alpha receptor activity. Technically
labetalol has both alpha and beta receptor
blocking activity, therefore the risk of unopposed alpha activity is not thought to be high.
Other options include hydralazine and nitroprusside. ACE inhibitors or ARBs are contraindicated in mothers who have not delivered due
to their teratogenicity. Although prolactin is
believed to play a role in PPCM, the use of bromocriptine (a dopamine receptor agonist that
inhibits prolactin secretion) is not an approved
treatment.
In addition to medical management, patients
with MAC will need appropriate treatment of
their addiction as this will ultimately determine their long-term prognosis. A University of
Hawaii study found that implementation of a
“harm-reduction model” consisting of services
such as addiction medicine, social services and
perinatal care yielded improvement in birth
outcomes and a reduction in subsequent positive urine drug tests.14
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The prognosis in PPCM is generally favorable as
a recovery of ejection fraction (LVEF >50%) is
typically seen within 6 months.8 Several factors
have been associated with a higher likelihood of
recovery, such as LVEF above 30% at the time
of diagnosis, Caucasian race and diagnosis in
the postpartum period.15,16 This phenomenon of
reversibility is also documented in patients with
MAC. The primary factor contributing to recovery is cessation of methamphetamine use.11,17 It’s
important to note that a majority of this data
is from methamphetamine use in non-pregnant
adults, and more data assessing outcomes of
methamphetamine use specifically in the obstetric population is needed.
Another etiology of reversible cardiomyopathy
that warrants discussion given the rapid recovery of EF, is stressed cardiomyopathy (also
known as Takotsubo cardiomyopathy and apical
ballooning syndrome). It is typically precipitated
by profound emotional or physical stress, and it
usually occurs in post-menopausal women, but
cases have been documented in pregnancy. Given the patient was using methamphetamine,
the combination of a hyperadrenergic state and
pregnancy makes stress-induced cardiomyopathy a plausible diagnosis.
There are, however, several factors in this case
which we believe make stress cardiomyopathy less likely: normal troponin levels, patterns
on electrocardiography (EKG) and echocardiographic findings that overall do not fit the
stigmata of stress-induced cardiomyopathy.
The patient had three serial troponin levels
measured, which were negative. A study using
data from the International Takotsubo Registry
found that 80% of patients with stress-induced
cardiomyopathy had troponin elevation.18 QT
prolongation and ST segment changes (typically elevation) are also a common finding. The
patient in our case had an average corrected
QT interval of 458 (considered within borderline range for females based on the Journal of
American College of Cardiology classification)
with no ST segment elevation or depression on
three serial EKGs.18-20 The stat echocardiogram
mentioned previously, demonstrated moderate
diffuse hypokinesis of the left ventricle and a
normal size, rather than the classic pattern of
apical akinesis and basal hyperkinesis seen in
the majority of patients with stress-induced
cardiomyopathy.20,21 Right ventricular apical in-

volvement is also seen in up to 25% of patients,
although the patient’s right ventricle size and
systolic function were reported to be normal.21
Based on this data we henceforth conclude
that a diagnosis of MAC is more likely than
stress-induced cardiomyopathy.

Conclusion

The treatment for methamphetamine associated cardiomyopathy and peripartum cardiomyopathy are essentially the same as the
treatment of an acute heart failure exacerbation and both etiologies are potentially reversible causes of cardiomyopathy. Nevertheless,
current evidence clearly shows a distinction in
the pathophysiology between MAC, which is
due to a hyperadrenergic state, versus PPCM,
which is due to an adverse hormonal effect
on the maternal vasculature and cardiac myocytes. Stress-induced cardiomyopathy shares
a common pathophysiology with MAC; however, it has distinct echocardiographic features
which weren’t seen in this case. We can effectively conclude that the patient’s symptoms
were secondary to MAC rather than PPCM or
stress-induced cardiomyopathy. Studies involving methamphetamine use in pregnancy are
limited and ultimately more longitudinal data
is needed to achieve a better understanding of
patient outcomes.
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